Radiopharm (RADX) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $16.00 | Jun 4, 2026 |
| B. Riley Securities | Maintained | Buy | $16.00 from $13.00 | Dec 16, 2025 |
| B. Riley Securities | Maintained | Buy | $13.00 from $15.00 | Nov 26, 2025 |
| Brookline Capital | Initiated Coverage | Buy | $18.00 | Jul 21, 2025 |
| Maxim Group | Initiated Coverage | Buy | $12.00 | May 1, 2025 |
| B. Riley Securities | Initiated Coverage | Buy | $15.00 | Mar 12, 2025 |
Frequently asked questions
Is RADX a buy, sell, or hold?
Analysts covering Radiopharm currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RADX?
On Jun 4, 2026, HC Wainwright & Co. initiated coverage of Radiopharm at Buy with a price target of $16.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.